Intranasal Deferoxamine Provides Increased Brain Exposure and Significant Protection in Rat Ischemic Stroke

Deferoxamine (DFO) is a high-affinity iron chelator approved by the Food and Drug Administration for treating iron overload. Preclinical research suggests that systemically administered DFO prevents and treats ischemic stroke damage and intracerebral hemorrhage. However, translation into human trial...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Hanson, Leah R., Roeytenberg, Annina, Martinez, Paula M., Coppes, Valerie G., Sweet, Donald C., Rao, Reshma J., Marti, Dianne L., Hoekman, John D., Matthews, Rachel B., Frey, William H., Panter, S. Scott
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Pharmacology and Experimental Therapeutics 2009
Assuntos:
Neuropharmacology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2729791/
https://ncbi.nlm.nih.gov/pubmed/19509317
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.108.149807
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares